{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-014892","form_type":"8-K","ticker":"URGN","cik":"0001668243","company_name":"UroGen Pharma Ltd.","filed_at":"2022-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.719709+00:00","generated_at":"2026-06-25T02:23:44.938317+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"UroGen shareholders reject say-on-pay and compensation policy; approve equity plan increase","bullets":["Advisory vote on executive compensation failed: 5.7M against vs 4.2M for.","Amendment to compensation policy under Israeli law not approved: 2.5M for, 4.9M against.","Equity plan amendment (increase by 400K shares) approved narrowly: 5.3M for, 4.5M against.","PricewaterhouseCoopers ratified as independent auditor with 14.2M votes for.","All six director nominees elected, with Arie Belldegrun receiving 7.5M votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-014892","json":"https://secwatch.observer/filing/0001437749-22-014892.json","markdown":"https://secwatch.observer/filing/0001437749-22-014892.md","text":"https://secwatch.observer/filing/0001437749-22-014892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922014892/0001437749-22-014892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1668243/000143774922014892/urgn20220610_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T02:23:44.938317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}